The Patent Finder

Method of Purifying Proteins

CSL Behring GmbH

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 61/709,342, filed Oct 3, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 9,937,229Methods of Treatment Using Hemopexin Compositions
In force
 · High confidence
UsedRemaining
CSL Behring AGIn forceHigh confidence
US 9,534,029Method of Purifying Proteins
In force
 · High confidence
CSL Behring AGIn forceHigh confidence
US 10,918,696Methods of Treatment Using Hemopexin Compositions
Lapsed Feb 16, 2025 on the fee record
High confidence
CSL Behring AGLapsed Feb 16, 2025 on the fee recordHigh confidence
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by CSL Behring GmbH.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited